Ramos MME, Bastidas RBE, Carrillo PMC

Language: Spanish
References: 13
Page: 61-63
PDF size: 151.17 Kb.

ABSTRACT

Progressive liver fibrosis is the main cause of organ failure in chronic liver diseases of any etiology. Fibrosis develops with different spatial patterns and it’s a consequence of different prevalent mechanisms according to the diverse causes of parenchymal damage. Liver biopsy is the gold standard method to assess inflammatory activity and fibrosis stage, but this is associated with morbidity and mortality. There is a compelling need for non-invasive methods of liver fibrosis given the limitations of currently available methods of fibrosis assessment. “Serum markers” broadly refers to the measurement of one or more molecules within a blood or serum sample as a surrogate marker of fibrosis in the liver. Possible applications of non-invasive markers will include both the initial assessment and monitoring of antiviral of antifibrotic therapy, and may additionally provide new information about the natural history of fibrosis progression and regression.

REFERENCES

1. Zhen M, Cai W, Weng H, Liu R. Determination of serum fibrosis indexes in patients with chronic hepatitis and its significance. Chin Med J, 2003;116(3):346-349.

2. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis, 2004;36(4):231-242.

3. Kershenobich SD, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann Hepatol, 2003;2(4):159-163.

4. Poynard T, Raiziu V Bedossa P. Appropriateness of liver biopsy. Con J Gastroenterol, 2000;14:543-548.

5. Maharaj B, Maharaj RJ, Leary WP, Copan RM, Naran AD, Pirie D Pudifin DJ. Sampling variability and its influence on the diagnostic yiel of percutaneous needle biopsy of the liver. Lancet, 1986;1(8480):523-525.

6. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol, 2003;39:179-186.

7. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matriz protein of specific granules in human neutrophils. Proc Assoc Am Physicians, 1998;110(4):351-360.

8. Johansen JS, Moller S, Price PA, Bendtsen F, Junge J, Garabarsch C, Henriksen JH. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholi cirrhosis?. Scand J Gastroenterol, 1997;32(6):582-590.

9. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Bajoan EM, Demuth N, Longo F, Rampal P. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol, 2000;12(9):989-993.

10. Johansen JS, Christofferson P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol, 2000;32(6):911-920.

11. Smedsrod B. Aminoterminal propeptide of Tipe III procollagen is cleared from the circulation by receptor-mediated endocitosis in liver endotelial cells. Coll Relat Res, 1988;8:375-388.

12. Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, Conradt C, McCuskey RS, Simanowski UA, Seitz HK. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci, 2001;46(9):2025-2032.

13. Serejo F, Costa A, Olivera AG, Ramalho F, Batista A, De Moura MC. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N- terminal propeptide of procollagen type III. Dig Dis Sci, 2001;46(8):1684-1689.